Login to Your Account

GPC Shares Battered Again

'Major Setback' As Satraplatin Fails To Improve Overall Survival

By Jennifer Boggs

Thursday, November 1, 2007
After progression-free survival data for satraplatin failed to wow an FDA advisory committee in July, GPC Biotech AG, along with partners Pharmion Corp. and Spectrum Pharmaceuticals Inc., hoped the drug's overall survival data would be impressive enough to clear the way for approval in second-line hormone-refractory prostate cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription